TG Therapeutics (NASDAQ:TGTX) Upgraded at StockNews.com

StockNews.com upgraded shares of TG Therapeutics (NASDAQ:TGTX) from a sell rating to a hold rating in a report released on Tuesday.

A number of other analysts have also weighed in on the stock. HC Wainwright increased their price objective on shares of TG Therapeutics from $49.00 to $55.00 and gave the stock a “buy” rating in a research report on Tuesday, November 5th. The Goldman Sachs Group boosted their price objective on TG Therapeutics from $20.00 to $22.00 and gave the company a “neutral” rating in a report on Tuesday, November 5th. TD Cowen started coverage on TG Therapeutics in a research note on Tuesday, October 29th. They issued a “buy” rating and a $50.00 target price on the stock. Finally, JPMorgan Chase & Co. boosted their target price on shares of TG Therapeutics from $30.00 to $43.00 and gave the company an “overweight” rating in a research note on Monday, November 25th. Two research analysts have rated the stock with a hold rating and five have given a buy rating to the company’s stock. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $40.67.

TG Therapeutics Price Performance

NASDAQ:TGTX opened at $28.77 on Tuesday. The firm has a market capitalization of $4.48 billion, a price-to-earnings ratio of -287.67 and a beta of 2.24. The company has a debt-to-equity ratio of 1.27, a current ratio of 4.59 and a quick ratio of 3.91. The business has a 50 day simple moving average of $31.45 and a 200-day simple moving average of $25.28. TG Therapeutics has a 1 year low of $12.84 and a 1 year high of $36.84.

TG Therapeutics (NASDAQ:TGTX) last posted its quarterly earnings data on Monday, November 4th. The biopharmaceutical company reported $0.02 EPS for the quarter, missing the consensus estimate of $0.03 by ($0.01). TG Therapeutics had a negative return on equity of 8.32% and a negative net margin of 5.42%. The firm had revenue of $83.90 million for the quarter, compared to analysts’ expectations of $81.68 million. During the same period in the previous year, the firm earned $0.73 earnings per share. The firm’s quarterly revenue was down 49.4% compared to the same quarter last year. Equities analysts forecast that TG Therapeutics will post 0.17 EPS for the current year.

Insider Activity

In other news, CFO Sean A. Power sold 11,337 shares of TG Therapeutics stock in a transaction on Friday, January 3rd. The stock was sold at an average price of $30.29, for a total value of $343,397.73. Following the transaction, the chief financial officer now directly owns 670,632 shares in the company, valued at approximately $20,313,443.28. This trade represents a 1.66 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, Director Sagar Lonial sold 5,000 shares of the business’s stock in a transaction on Monday, November 11th. The stock was sold at an average price of $30.44, for a total value of $152,200.00. Following the completion of the transaction, the director now directly owns 100,195 shares of the company’s stock, valued at approximately $3,049,935.80. The trade was a 4.75 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 26,358 shares of company stock worth $781,497. Company insiders own 10.50% of the company’s stock.

Hedge Funds Weigh In On TG Therapeutics

A number of large investors have recently added to or reduced their stakes in TGTX. Oppenheimer & Co. Inc. purchased a new position in shares of TG Therapeutics in the 3rd quarter worth approximately $759,000. Segall Bryant & Hamill LLC purchased a new position in TG Therapeutics in the third quarter worth $1,225,000. Barclays PLC increased its position in shares of TG Therapeutics by 83.9% during the third quarter. Barclays PLC now owns 347,057 shares of the biopharmaceutical company’s stock worth $8,117,000 after purchasing an additional 158,323 shares in the last quarter. Principal Financial Group Inc. lifted its holdings in shares of TG Therapeutics by 1,549.4% during the 3rd quarter. Principal Financial Group Inc. now owns 772,188 shares of the biopharmaceutical company’s stock valued at $18,061,000 after purchasing an additional 725,371 shares during the last quarter. Finally, Neo Ivy Capital Management purchased a new position in TG Therapeutics during the 3rd quarter worth $2,358,000. 58.58% of the stock is currently owned by institutional investors.

TG Therapeutics Company Profile

TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.